Loading...
Market
What will be Phathom Pharmaceuticals' total revenue for the fiscal year 2024?
3
Resolution / Starting Odds
Less than $200 million • 25%
$200 million to $300 million • 25%
$300 million to $400 million • 25%
More than $400 million • 25%
Phathom Pharmaceuticals' annual financial report
Story
Phathom Pharmaceuticals Receives FDA Approval for VOQUEZNA for GERD Heartburn Relief in Adults
Jul 18, 2024, 12:04 PM
Phathom Pharmaceuticals has received FDA approval for its drug VOQUEZNA (vonoprazan) tablets. The medication is intended for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) in adults. This approval, announced on July 17 and July 18, marks a significant milestone for Phathom Pharmaceuticals, which has a short interest of over 40%. VOQUEZNA is a potassium-competitive acid blocker (PCAB), expanding its approval to cover more GERD patients.
View original story
Similar markets
Less than $85 billion • 25%
$85 billion to $90 billion • 25%
$90 billion to $95 billion • 25%
More than $95 billion • 25%
Below $45 billion • 25%
$45 billion to $45.5 billion • 25%
$45.5 billion to $46 billion • 25%
Above $46 billion • 25%
$45.4 billion to $46.6 billion • 25%
Less than $45.4 billion • 25%
More than $46.6 billion • 25%
Between $46.0 billion and $46.6 billion • 25%
More than 20% increase • 25%
10%-20% increase • 25%
0%-10% increase • 25%
Decrease • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Below $2.4 billion • 25%
$2.4 billion to $2.5 billion • 25%
$2.5 billion to $2.6 billion • 25%
Above $2.6 billion • 25%
Below $27.1 billion • 25%
$27.1 billion to $27.3 billion • 25%
$27.31 billion to $27.5 billion • 25%
Above $27.5 billion • 25%
Less than $300M • 33%
$300M - $500M • 33%
More than $500M • 33%
Below $8 billion • 25%
$8 billion to $10 billion • 25%
$10 billion to $12 billion • 25%
Above $12 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $3 billion • 25%
$3 billion to $3.5 billion • 25%
$3.5 billion to $4 billion • 25%
More than $4 billion • 25%